Merck is in advanced talks to buy Revolution Medicines for up to $32 billion, a high-stakes swing at shoring up its post-Keytruda pipeline as the 2028 patent cliff nears. Revolution Medicines shares traded around $123.65 after the report, signaling investor optimism that a deal premium is coming and a bidding war is possible. The structure could include milestones, and timing remains fluid.
For Merck, this is about time. Keytruda, the world’s top-selling cancer drug, comes off patent in 2028, and while the company has pushed life-cycle strategies and new indications, the core cash flows face erosion as biosimilars emerge. Management has been clear: business development is a pillar of the offset plan. The recent $10.5 billion purchase of Verona Pharma broadened cardio-pulmonary, but the message here is that oncology remains the franchise Merck intends to defend with scale. Paying up to $32 billion for Revolution Medicines would rank as one of Merck’s largest innovation buys and underscores the urgency to add de-risked late-clinical assets that can be commercial by the turn of the decade. Investors may debate price discipline, but the strategic logic is straightforward: buy speed and optionality when the calendar is your enemy.
Revolution Medicines’ hook is zoldonrasib, a lead oncology asset that has secured FDA Breakthrough Therapy Designation in a defined subset of non-small cell lung cancer. Breakthrough status doesn’t guarantee approval, but it signals encouraging clinical activity and a potential expedited review if pivotal data hold. The company has also highlighted applicability in pancreatic cancer, a brutal indication with few effective options and significant unmet need. That optionality matters. If zoldonrasib can anchor a franchise across RAS-driven tumors, Merck gains a foothold in one of oncology’s most competitive targets, with read-through across combinations and lines of therapy. Expect Merck to lean into trial synergies and explore combinations across its oncology portfolio to maximize addressable segments. The bet is not just on one drug, but on a platform approach to RAS biology that could scale if the early signals translate.
The reported price tag “up to $32 billion” suggests a tiered structure, likely cash up front with contingent value rights tied to regulatory or commercial milestones. That framing protects the buyer on downside clinical scenarios while allowing the seller to capture upside if the pipeline delivers. With Revolution Medicines changing hands around $123.65 in recent trading, the tape implies investors see room to the mid-$120s or above on a formal offer, depending on the earnout terms. The headline number will be debated, but in a zero-revenue biotech with a Breakthrough-designated lead and multiple shots on goal, valuation anchors to probability-weighted peak sales and speed to market. Merck can afford the check; Keytruda and vaccines spin off robust cash, and the balance sheet remains investment grade. The shareholder question is whether this is the highest-return use of capital versus buybacks or smaller tuck-ins. On a multi-year view, if zoldonrasib proves out in lung and cracks even a slice of pancreatic, the return profile can justify a premium. If it stumbles, the price will look rich in hindsight.
This may not be a one-horse race. Other large pharma names are said to be circling Revolution Medicines, an obvious outcome given the scarcity value of late-stage, Breakthrough-designated oncology assets targeting ubiquitous mutations. Competitive pressure is how you get to “up to $32 billion.” On precedent, big oncology assets rarely change hands without a process, and auctions can drag timelines and push structures toward earnouts to reconcile buyer caution with seller expectations. The year’s M&A tape has validated that appetite is back: megadeals like Pfizer’s buy of Seagen reset the bar on how far strategics will go to buy growth they can underwrite. If rival bidders emerge, Merck will have to decide how far to stretch without compromising returns, and Revolution’s board will test for price and certainty. The presence of multiple suitors, even rumored, typically tightens terms and compresses closing risk for the eventual winner.
On antitrust, oncology draws attention, but the market structure and asset profile here point to an approvable path. Revolution Medicines doesn’t market an approved therapy yet, and while Merck is a dominant oncology player, the overlap without marketed competition is limited. U.S. regulators have scrutinized pharma roll-ups more aggressively, but headline deals focused on pipeline additions with minimal horizontal concentration have generally cleared with standard remedies, if any. The more complex gating item could be regulatory risk at the FDA level, not antitrust: Breakthrough Therapy Designation shortens the path if the data cooperate, but it does not eliminate the need for robust, reproducible efficacy across well-defined patient populations. That is clinical execution, not competition law, and it is where many high-priced oncology bets succeed or fail.
The clinical calendar is perhaps the most important variable. Drugs with Breakthrough status can still face setbacks in larger, randomized studies. Pancreatic cancer has humbled many pedigreed assets. The revenue window that matters for Merck is the late-2020s to early-2030s; that’s when Keytruda erosion bites and when a new oncology franchise would need to step in with material sales. Even optimistic scenarios usually require a couple of years from approval to peak contribution in complex oncology launches. That means Merck is buying not just a trial result but a commercialization and access campaign that has to move fast and globally. It also means the company will keep doing deals; a single asset is unlikely to bridge the entire Keytruda gap. This is a portfolio solution—zoldonrasib as a core pillar, supplemented by earlier-stage shots and lifecycle extensions elsewhere in immuno-oncology.
For biotech, the signal is loud: late-stage, de-risked oncology assets with clear biomarker-defined populations command premium valuations again, particularly when they plug a buyer’s looming revenue hole. Boards will point to Revolution Medicines as a benchmark on structure and pricing. For big pharma, the message is that the window is open to transact at scale, but discipline and speed matter. Competitive processes drive earnouts higher and blur valuation optics; sitting out can leave a pipeline gap that is harder and more expensive to close later. Investors will parse who else could be in play across RAS-driven oncology and adjacent modalities. They will also watch how Merck communicates combined R&D plans, cost of capital, and return thresholds to justify the checkbook.
Talks are advanced but weeks from the finish line, according to people familiar, and the contours could shift as diligence deepens. Expect further headlines on deal structure, potential rival bids, and timing. Revolution Medicines shareholders will focus on certainty, cash mix, and CVR triggers. Merck investors will look for clarity on the pro forma impact to earnings trajectory, leverage, and how zoldonrasib slots into the oncology strategy alongside existing immunotherapy anchors. If the deal closes near the reported terms, Merck will have bought time and a credible shot at a next-wave oncology franchise. If a bidding war breaks out, the market will get a fresh test of just how far big pharma is willing to go to buy growth before the patent cliffs hit.
